# Blanca Homet Moreno

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/blanca-homet-moreno/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,299 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 38 |
| i10-index | 62 |
| Last Known Institution | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| OpenAlex ID | https://openalex.org/A5082742595 |
| ORCID iD | https://orcid.org/0000-0001-6712-8330 |
| Works | 183 |

## Researcher papers

- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

## Researcher university

- [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.